Metronidazole Unifarma (Metronidazole)

Metronidazole is taken up by anaerobic bacteria and certain protozoa, where intracellular nitroreductases reduce its nitro group. This reduction creates reactive nitro radicals that damage DNA and inhibit nucleic acid synthesis, ultimately leading to cell death of the targeted microorganisms while sparing most human cells.

The dosage of Metronidazole Unifarma is individualized by the prescriber according to the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals determine the appropriate dose, frequency, and duration for each patient.

Safety data for Metronidazole in pregnancy and lactation are limited, and the drug is generally classified as a precautionary agent. Clinicians weigh potential benefits against possible risks before prescribing to pregnant or nursing individuals, and alternative therapies may be considered when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms and certain protozoa, offering a narrow spectrum that minimizes disruption of normal flora. Compared with broad‑spectrum agents like clindamycin or carbapenems, it provides effective coverage for many anaerobic pathogens with a generally favorable safety profile, though choice depends on susceptibility patterns and infection site.

Metronidazole Unifarma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and sterility.

Metronidazole Unifarma is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel under aseptic conditions, following the prescribed infusion rate and duration as directed by the treating physician.

Serious adverse events, though rare, include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, liver toxicity, and pancytopenia. Patients should be monitored for neurological symptoms, skin changes, or signs of bleeding, and therapy should be discontinued if any serious reaction occurs.

Metronidazole Unifarma is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic impairment, those receiving disulfiram, and patients with a history of seizures or peripheral neuropathy unless the benefits outweigh the risks.